Faster drug approval: challenges for safety

Area of Science:

• Pharmacovigilance
• Drug Safety Evaluation
• Regulatory Science

Background:

• Rapid drug premarketing procedures present challenges for regulatory agencies regarding innovation and real-world safety.
• Balancing swift market access with thorough safety and effectiveness evaluation is crucial.

Purpose of the Study:

• To review blockbuster drugs over the past fifteen years, analyzing adverse reactions that emerged post-marketing.
• To identify key elements, timelines, and measures for risk identification and management.
• To provide expert opinion on improving drug risk prediction and post-marketing surveillance.

Main Methods:

• Literature review of existing studies and agency reports.
• Analysis of adverse reactions reported after marketing for blockbuster drugs.
• Synthesis of expert opinion on risk prediction factors and regulatory strategies.

Main Results:

• Risk prediction is enhanced by randomization, adequate sample size, clear safety endpoints, comparator use, and extended Phase-III trials.
• Early detection of adverse events can be achieved through advanced biochemical, instrumental, and imaging techniques.
• Comparative non-inferiority trials should prioritize safety, except for critical diseases with limited treatment options.

Conclusions:

• A period of restricted use may be necessary for new drugs to facilitate early adverse event detection.
• New medicines should not be assumed to be superior until widespread use provides further evidence.
• Regulatory agencies must adapt to balance innovation with robust post-marketing safety monitoring.